← All trials
NCT06405100
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Apr 30, 2027
- First posted
- May 8, 2024
- Last posted
- May 8, 2024
- Enrollment
- 81
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Air Force Military Medical University, ChinaLead sponsor
- Air Force Military Medical University, ChinaSponsor investigator
- Jiao Tong UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Air Force Military Medical University, ChinaCollaborator
- Shaanxi Provincial People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.